<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01712867</url>
  </required_header>
  <id_info>
    <org_study_id>Vayarol_006</org_study_id>
    <nct_id>NCT01712867</nct_id>
  </id_info>
  <brief_title>The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels</brief_title>
  <official_title>The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels in Hypertriglyceridemia Patients: A Double-blind, Randomized, Noninferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzymotec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Enzymotec</source>
  <brief_summary>
    <textblock>
      The primary objective is to determine the efficacy of phytosterol esters of omega-3 (Vayarol)
      versus Omega-3 acids ethyl esters in reducing triglyceride levels in hypertriglyceridemia
      patients with fasting triglyceride levels ≥ 200 and &lt; 500 mg/dL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting triglycerides levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>Noninferiority of phytosterol esters of omega-3 in affecting plasma fasting triglyceride levels in comparison with Omega-3 acids ethyl esters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between phytosterol esters of omega-3 and Omega-3 acids ethyl esters treatment groups in other lipid and biomarker levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>Difference between phytosterol esters of omega-3 and Omega-3 acids ethyl esters treatment groups in other lipid and biomarker levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Patients With Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Phytosterol esters of omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 capsules/day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 acid ethyl esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 capsules/day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Omega-3 acid ethyl esters</intervention_name>
    <description>4 capsules/day for 12 weeks</description>
    <arm_group_label>Omega-3 acid ethyl esters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phytosterol esters of omega-3</intervention_name>
    <description>4 capsules/day for 12 weeks</description>
    <arm_group_label>Phytosterol esters of omega-3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age &gt; 18 years

          2. Triglycerides ≥ 200 mg/dL and &lt; 500 mg/dL

          3. Ability to give written informed consent

        Exclusion Criteria:

          1. Female patient who are pregnant or breastfeeding or planning to become pregnant

          2. Fasting plasma glucose (FPG) levels &gt; 110 mg/dL

          3. Type 2 diabetes mellitus that is poorly controlled (glycosylated hemoglobin [HbAlc ]
             &gt;8.0%

          4. Patients who are under use of lipid altering drugs excluding use of Simvastatin,
             Atorvastatin, and Rosovastatin for 6 weeks or more

          5. Patients who are under use of products containing omega-3 fatty acids or other dietary
             supplements with potential lipid altering effects

          6. History of bariatric surgery or currently on weight loss drugs.

          7. Uncontrolled hypertension (BP&gt;140/90)

          8. Subjects with secondary causes of hypertriglyceridemia: alcoholism, dysglobulinemia,
             thyroid disease that is poorly controlled (TSH&lt;0.35 or TSH&gt;5.5)

          9. Subjects with an abnormal level of liver enzymes (twice the normal level)

         10. Suffered from ischemic event such as myocardial infarction, cerebrovascular accident
             and angina pectoris in the last 6 months

         11. Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins such as cushing syndrome

         12. Gastrointestinal disease that may influence lipid metabolism such as celiac, crohn,
             colitis or other malabsorption problem

         13. Subjects who have had any malignancy. Subjects who have had basal cell carcinoma that
             have been disease free for at least 3 years are eligible for the study.

         14. Consumption of one fish serving (200 grams) or sea food x2 a week or more.

         15. HIV infection by history

         16. History of hypersensitivity or allergy to fish, fish oil or soy

         17. BMI≥35

         18. Weight change &gt; 3 kg during the run-in period

         19. Any other reason that, in the opinion of the investigator, prevents the subject from
             participating in the study or compromise the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yossi Azuri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maccabi Healthcare Services, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maccabi Healthcare Services</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>October 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

